東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

T Cell Evolution in the Blood and Or...

Omdahl, Kayleigh Ingersoll,

FindBook

Google Book

Amazon

博客來

T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease // Kayleigh Ingersoll Omdahl.
作者:	Omdahl, Kayleigh Ingersoll,
面頁冊數:	1 electronic resource (161 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
Contained By:	Dissertations Abstracts International86-12B.
標題:	Immunology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=32040375
ISBN:	9798280713079

T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease /
Omdahl, Kayleigh Ingersoll,

T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease /Kayleigh Ingersoll Omdahl. - 1 electronic resource (161 pages)

Source: Dissertations Abstracts International, Volume: 86-12, Section: B.

Hematopoietic Stem Cell Transplantation (HSCT) can be curative for a variety of diseases, including hematologic malignancies, immunodeficiencies, and bone marrow failure syndromes. Graft-Versus-Host Disease (GVHD) remains one of the deadliest complications of HSCT. Even with the use of current GVHD prophylaxis regimens, which are broadly acting, non-targeted agents, GVHD still occurs in 50-80% of allogeneic transplant recipients. There is a need for more selective therapies to prevent GVHD while still preserving the protective effects of the immune system. T cells are the main instigators of acute GVHD (aGVHD), given that their removal ameliorates this disease. However, their removal does not decrease transplant mortality, due to diminished engraftment, increased relapse, and higher risks of infection. Considering the essential protective effects of T cells as well as their role in GVHD, better understanding and targeting of alloreactive T cells while preserving non-pathogenic T cells will be important for the future of HSCT.Chapter two describes our investigations into T cell programming changes that occur in the liver and lungs during aGVHD in non-human primates (NHP) and identified organ-specific gene expression programs specific to the lung and liver. We demonstrated how these programs developed through clonal expansion of the T cells within the organ-microenvironment in an antigen-independent manner. These discoveries laid a foundation for better targeted and possible organ-specific treatment development for aGVHD in the future.Chapter three describes our investigation of candidate GVHD-modifying gene edits in a xenogeneic model of aGVHD, using CRISPR/Cas9-edited human T cells transplanted into immunodeficient (NSG) mice. We edited target genes that were implicated in aGVHD T cell pathogenesis and evaluated how their deletion affected aGVHD development in the model. We focused on RGS1 for its role in aGVHD development, with results suggesting that knocking out RGS1 could decrease aGVHD.Chapter four describes our evaluation of the differences in T cell reconstitution after clinical HSCT in two cohorts of patients treated with distinct GVHD prophylaxis regimens: tacrolimus and methotrexate (Tac/MTX) compared to post-transplant cyclophosphamide, tacrolimus and MMF (PT-Cy). Additionally, we evaluated the differences in T cell gene expression programs when patients developed aGVHD in the two cohorts. We found evidence for wholesale T cell depletion with PT-Cy, resulting in long term deficits in TCR diversity, relative enriched contributions of host-derived cells, and prolonged deficits in naive T cells compared to patients receiving Tac/MTX. T cell subsets in patients who developed aGVHD in either cohort demonstrated distinct immune activation patterns.The data presented in this thesis evaluate T cell reconstitution in the blood and organs of two model systems, mice and NHP, as well as human clinical trial samples, to further understand how T cells evolve throughout HSCT and the development of aGVHD. These discoveries have implications for the efficacy and toxicity of current aGVHD prophylaxis regimens, as well as for developing aGVHD prevention and treatment using targeted agents in the future.

English

ISBN: 9798280713079Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Bone marrow transplant

T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease /
LDR:04784nmm a22004453i 4500 001 2433858
005 20250905091028.5
006 m o d
007 cr|nu||||||||
008 261011s2025 miu||||||m |||||||eng d
020 $a 9798280713079
035 $a (MiAaPQD)AAI32040375
035 $a AAI32040375
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Omdahl, Kayleigh Ingersoll, $e author. $0 (orcid)0000-0003-0255-5547 $3 3823629
245 1 0 $a T Cell Evolution in the Blood and Organs During Acute Graft-Versus-Host Disease / $c Kayleigh Ingersoll Omdahl.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2025
300 $a 1 electronic resource (161 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-12, Section: B.
500 $a Advisors: Kean, Leslie Committee members: Ordovas-Montanes, Jose; Clark, Rachael; Sen, Debattama; Perales, Miguel-Angel.
502 $b Ph.D. $c Harvard University $d 2025.
520 $a Hematopoietic Stem Cell Transplantation (HSCT) can be curative for a variety of diseases, including hematologic malignancies, immunodeficiencies, and bone marrow failure syndromes. Graft-Versus-Host Disease (GVHD) remains one of the deadliest complications of HSCT. Even with the use of current GVHD prophylaxis regimens, which are broadly acting, non-targeted agents, GVHD still occurs in 50-80% of allogeneic transplant recipients. There is a need for more selective therapies to prevent GVHD while still preserving the protective effects of the immune system. T cells are the main instigators of acute GVHD (aGVHD), given that their removal ameliorates this disease. However, their removal does not decrease transplant mortality, due to diminished engraftment, increased relapse, and higher risks of infection. Considering the essential protective effects of T cells as well as their role in GVHD, better understanding and targeting of alloreactive T cells while preserving non-pathogenic T cells will be important for the future of HSCT.Chapter two describes our investigations into T cell programming changes that occur in the liver and lungs during aGVHD in non-human primates (NHP) and identified organ-specific gene expression programs specific to the lung and liver. We demonstrated how these programs developed through clonal expansion of the T cells within the organ-microenvironment in an antigen-independent manner. These discoveries laid a foundation for better targeted and possible organ-specific treatment development for aGVHD in the future.Chapter three describes our investigation of candidate GVHD-modifying gene edits in a xenogeneic model of aGVHD, using CRISPR/Cas9-edited human T cells transplanted into immunodeficient (NSG) mice. We edited target genes that were implicated in aGVHD T cell pathogenesis and evaluated how their deletion affected aGVHD development in the model. We focused on RGS1 for its role in aGVHD development, with results suggesting that knocking out RGS1 could decrease aGVHD.Chapter four describes our evaluation of the differences in T cell reconstitution after clinical HSCT in two cohorts of patients treated with distinct GVHD prophylaxis regimens: tacrolimus and methotrexate (Tac/MTX) compared to post-transplant cyclophosphamide, tacrolimus and MMF (PT-Cy). Additionally, we evaluated the differences in T cell gene expression programs when patients developed aGVHD in the two cohorts. We found evidence for wholesale T cell depletion with PT-Cy, resulting in long term deficits in TCR diversity, relative enriched contributions of host-derived cells, and prolonged deficits in naive T cells compared to patients receiving Tac/MTX. T cell subsets in patients who developed aGVHD in either cohort demonstrated distinct immune activation patterns.The data presented in this thesis evaluate T cell reconstitution in the blood and organs of two model systems, mice and NHP, as well as human clinical trial samples, to further understand how T cells evolve throughout HSCT and the development of aGVHD. These discoveries have implications for the efficacy and toxicity of current aGVHD prophylaxis regimens, as well as for developing aGVHD prevention and treatment using targeted agents in the future.
546 $a English
590 $a School code: 0084
650 4 $a Immunology. $3 611031
650 4 $a Cellular biology. $3 3172791
650 4 $a Biostatistics. $3 1002712
650 4 $a Bioinformatics. $3 553671
653 $a Bone marrow transplant
653 $a Graft-Versus-Host Disease
653 $a T cells
653 $a Hematopoietic Stem Cell Transplantation
653 $a Non-human primates
690 $a 0982
690 $a 0379
690 $a 0308
690 $a 0715
710 2 $a Harvard University. $b Immunology. $e degree granting institution. $3 3823630
720 1 $a Kean, Leslie $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-12B.
790 $a 0084
791 $a Ph.D.
792 $a 2025
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=32040375